3-Aethyl-thiophan | 62184-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 3-Aethyl-thiophan
• 英文别名: 3-Ethylthiophan；3-ethyl-tetrahydro-thiophene；3-Aethyl-tetrahydro-thiophen；3-Ethyltetrahydrothiophene；3-ethylthiolane
• CAS: 62184-67-2
• 化学式: C₆H₁₂S
• 分子量: 116.227
• InChiKey: BEEJXKSVPBKHQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 aluminum oxide 、 硫化氢 作用下， 生成 3-Aethyl-thiophan
  参考文献：
  名称：

  Jur'ew; Gragerow, Zhurnal Obshchei Khimii, 1949, vol. 19, p. 724,728; engl. Ausg. S. 697

  摘要：

  DOI：

文献信息

• 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS
  申请人：Sabila Biosciences LLC

  公开号：US20180208584A1

  公开（公告）日：2018-07-26

  Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.

  该发明的组合物包括1,2-二硫杂环烷、二硫醇和相关化合物，可用作治疗剂，用于治疗和预防与EGFR活性异常相关的疾病和病况。
• [EN] PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO 3,4-B! PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASE DE TYPE 4 (PDE4)
  申请人：GLAXO GROUP LTD

  公开号：WO2005090348A1

  公开（公告）日：2005-09-29

  The invention provides a compound of formula (I) or a salt thereof: formula (I) wherein W is Ar, -CR4R5Ar or a group (y) or (y1), wherein Ar is (x) or (z): formulae (x), (z), (y), (y1) R1 is C1-4alkyl, C1-3fluoroalkyl or CH2CH2OH. R2 is C2-6alkyl, C3-6cycloalkyl or -(CH2)n4-C3-6cycloalkyl; and R3 is optionally substituted C3-8cycloalkyl, optionally substituted mono unsaturated C5-7cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc) (in which Y is O, S, SO2, or NR10), or a bicyclic group (ee): formulae (aa), (bb), (cc), (ee). The invention also relates to the use of the compounds in therapy as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis.

  该发明提供了式(I)的化合物或其盐：式(I)其中W是Ar，-CR4R5Ar或(y)或(y1)的基团，其中Ar是(x)或(z)：式(x)，(z)，(y)，(y1)；R1是C1-4烷基，C1-3氟代烷基或CH2CH2OH；R2是C2-6烷基，C3-6环烷基或-(CH2)n4-C3-6环烷基；R3是可选取代的C3-8环烷基，可选取代的单不饱和C5-7环烯基，可选取代的杂环基(aa)，(bb)或(cc)(其中Y是O，S，SO2或NR10)，或双环基(ee)：式(aa)，(bb)，(cc)，(ee)。该发明还涉及将该化合物用于治疗作为磷酸二酯酶IV(PDE4)的抑制剂，并/或用于治疗和/或预防炎症和/或过敏性疾病，例如慢性阻塞性肺疾病(COPD)，哮喘，类风湿性关节炎或过敏性鼻炎。
• Inhibitors of protein kinases
  申请人：Song Yonghong

  公开号：US20090298823A1

  公开（公告）日：2009-12-03

  The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及化合物I-II的公式及其药学上可接受的盐，酯和前药，它们是syk和/或JAK激酶的抑制剂。本发明还涉及制造这种化合物所使用的中间体，制备这种化合物的方法，包含这种化合物的制药组合物，抑制syk和/或JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗由syk和/或JAK激酶活性至少部分介导的许多疾病，如不良血栓形成和非何杰金淋巴瘤的方法。
• SLC2A TRANSPORTER INHIBITORS
  申请人：IOMET PHARMA LTD.

  公开号：US20160120863A1

  公开（公告）日：2016-05-05

  Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula: wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each X may be the same or different and is independently selected from C, N, O and S; R 1 and R 5 may be present or absent and may be the same or different and are each selected from H and a substituted or unsubstituted organic group; Z completes a ring with each X, each ring comprising from 3 to 8 ring atoms including the X, A, and Z, each ring atom being independently selected from C, N, O and S, and each ring atom being unsubstituted or independently substituted with H or a substituted or unsubstituted organic group; and wherein the bonds between all of the atoms in the rings including the X, A, and Z may independently be single bonds or double bonds, provided that when X or a ring atom is O or S the bonds to X are single bonds.

  提供了一种用于医药的SLC2A类I转运体抑制剂化合物，该化合物包括以下结构式：其中A和Z可以相同或不同，且分别独立地选自C、N、O和S；每个X可以相同或不同，且独立地选自C、N、O和S；R1和R5可以存在或不存在，可以相同或不同，且分别选自H和取代或未取代的有机基团；Z与每个X形成环，每个环包括从3到8个环原子，包括X、A和Z，每个环原子独立地选自C、N、O和S，并且每个环原子未取代或独立地取代H或取代或未取代的有机基团；其中，包括X、A和Z在内的所有环中的原子之间的键可以独立地为单键或双键，但当X或环原子为O或S时，与X的键为单键。
• Process for desulfurizing catalytically cracked gasoline
  申请人：MITSUBISHI OIL CO., LTD.

  公开号：EP0725126A1

  公开（公告）日：1996-08-07

  An efficient process for desulfurizing catalytically cracked gasoline, in which a reduction in olefin content is controlled to thereby minimize a reduction in octane number. A catalytically cracked gasoline is separated into a plurality of fractions including one or both of a fraction rich in sulfur compounds that are hard to desulfurize and a fraction rich in sulfur compounds that are easy to desulfurize. One or both of the fractions are subjected to hydrodesulfurization. The resulting fractions are then mixed with the remaining fractions.

  一种高效的催化裂化汽油脱硫工艺，可控制烯烃含量的减少，从而最大限度地降低辛烷值。将催化裂化汽油分离成多个馏分，其中包括富含硫化合物的难脱硫馏分和富含硫化合物的易脱硫馏分中的一种或两种。对其中的一种或两种馏分进行加氢脱硫。然后将得到的馏分与其余馏分混合。

表征谱图